Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

1,244

Participants

Timeline

Start Date

September 10, 2025

Primary Completion Date

October 30, 2031

Study Completion Date

December 30, 2031

Conditions

T2DM (Type 2 Diabetes Mellitus)CKD - Chronic Kidney Disease

Interventions

DRUG

ganagliflozin

50 mg Once daily, 120 weeks

DRUG

Placebo

50 mg Once daily, 120 weeks

Trial Locations (1)

Shanghai sixth People's Hospital, Shanghai

All Listed Sponsors

lead

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY